Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 2742

Sort by

Sort Order Select

Journal Articles

A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice

Blood (2021) 138 (14): 1258–1268.

https://doi.org/10.1182/blood.2020010331

Published: 2021

Includes: Supplemental data

Journal Articles

Structural characterization of a novel GPVI-nanobody complex reveals a biologically active domain-swapped GPVI dimer

Alexandre Slater, Ying Di, Joanne C. Clark, Natalie J. Jooss, Eleyna M. Martin, Fawaz Alenazy, Mark R. Thomas, Robert A. S. Ariëns, Andrew B. Herr, Natalie S. Poulter, Jonas Emsley, Steve P. Watson

Blood (2021) 137 (24): 3443–3453.

https://doi.org/10.1182/blood.2020009440

Published: 2021

Includes: Multimedia, Supplemental data

Journal Articles

Protease activity in single-chain prekallikrein

Ivan Ivanov, Ingrid M. Verhamme, Mao-fu Sun, Bassem Mohammed, Qiufang Cheng, Anton Matafonov, S. Kent Dickeson, Kusumam Joseph, Allen P. Kaplan, David Gailani

Blood (2020) 135 (8): 558–567.

https://doi.org/10.1182/blood.2019002224

Published: 2020

Includes: Supplemental data

Journal Articles

Characterisation of Citrullinated TFPI and Truncated TFPI Constructs By PAD4 in Model and Plasma Systems

M.G.L. Christella D. Thomassen, Dennis P.L. Suylen, Tilman M. Hackeng, PhD, Rory R. Koenen, PhD

Blood (2019) 134 (Supplement_1): 2390.

https://doi.org/10.1182/blood-2019-131190

Published: 2019

Journal Articles

In Vitro and In Vivo Characterization of Marstacimab, an Anti-TFPI Antibody

Chuenlei Parng, PhD, Macy Jin, PhD, Matthew Holsti, PhD, Susan Benard, Swapnil Rakhe, MS, Sunita R. Patel-Hett, PhD, Alison Joyce, Rob Webster, Debra D Pittman, MS

Blood (2019) 134 (Supplement_1): 2391.

https://doi.org/10.1182/blood-2019-130327

Published: 2019

Journal Articles

Prospective Controlled Monitoring of Hemlibra Prophylaxis Initiation in a Large Cohort of Hemophilia a Patients- Real World Data

Assaf Arie Barg, Tami Livnat, PhD, Tami Brutman-Barazani, Nurit Rosenberg, Ivan Budnik, MD PhD, Gili Kenet

Blood (2019) 134 (Supplement_1): 2397.

https://doi.org/10.1182/blood-2019-122010

Published: 2019

Journal Articles

Analysis of Platelet Alpha and Dense Granule Release Using Small Volumes of Blood

Joseph Cho, MD PhD, Melissa Tjota, MD PhD, Jocelyn Gutierrez, BSMT, Krzysztof Mikrut, BSMT(ASCP), Geoffrey D. Wool, MD PhD, Jonathan L Miller, MD PhD

Blood (2019) 134 (Supplement_1): 2342.

https://doi.org/10.1182/blood-2019-131258

Published: 2019

Journal Articles

Comparison of Bypassing Agents in Patients on Emicizumab Using Global Hemostasis Assays

Hande Kizilocak, Elizabeth Marquez-Casas, BS, Jemily Malvar, MS, Roxana Carmona, MD, Guy Young, MD

Blood (2019) 134 (Supplement_1): 904.

https://doi.org/10.1182/blood-2019-132050

Published: 2019

Journal Articles

Oxphos Inhibition Induces Formation of Tunneling Nanotubes in AML Cells and Facilitates Mitochondrial Transfer from BM Stroma to AML That Contributes to Microenvironment-Mediated Drug-Resistance of AML

Blood (2019) 134 (Supplement_1): 911.

https://doi.org/10.1182/blood-2019-125007

Published: 2019

Journal Articles

Expansion of Prior Existing TP53 Mutated Clones in Polycythemia Vera Patients Treated with Idasanutlin

Bridget Marcellino, MD PhD, Bruno Cassinat, PharmD, PhD, Noushin Farnoud, PhD, Min Lu, PhD, Emmanuelle Verger, PhD, Erin McGovern, BA, Minal A Patel, MPH, Heidi E. Kosiorek, MS, Meenakshi Mehrotra, PhD, Jane Houldsworth, PhD, Amylou C. Dueck, PhD, Michael Rossi, PhD, Jean-Jacques Kiladjian, MD PhD, Raajit K. Rampal, MD PhD, John Mascarenhas, MD, Ronald Hoffman, MD

Blood (2019) 134 (Supplement_1): 838.

https://doi.org/10.1182/blood-2019-128342

Published: 2019

Journal Articles

Exploiting the Zinc Finger Degrome Targeted By Lenalidomide to Engineer Reversible Off-Switch Degradable Chimeric Antigen Receptors

Max Jan, MD PhD, Ana Castano, MD, Amanda Walker, BA, Andrew A Guirguis, MD PhD, Jessica A Gasser, PhD, Amanda A Bouffard, Mikolaj Slabicki, PhD, Alexander Tepper, Daniel E Grinshpun, Taeyoon Kyung, PhD, Quinlan Sievers, MD PhD, Michael E Birnbaum, PhD, Marcela V Maus, MD PhD, Benjamin L. Ebert, MD PhD

Blood (2019) 134 (Supplement_1): 866.

https://doi.org/10.1182/blood-2019-124210

Published: 2019

Journal Articles

Glutaminase Inhibition Overcomes Acquired Resistance to Mitochondrial Complex I in NOTCH1-Driven T-Cell Acute Lymphoblastic Leukemias (T-ALL) Via Block of Glutamine Driven Reductive Metabolism

Blood (2019) 134 (Supplement_1): 806.

https://doi.org/10.1182/blood-2019-128930

Published: 2019

Journal Articles

A Novel Combination Regimen of BET and FLT3 Inhibition for FLT3-ITD Acute Myeloid Leukemia

Lauren Lee, Yoshiyuki Hizukuri, Paul Severson, Ben Powell, PhD, Chao Zhang, PhD, Yan Ma, Maiko Narahara, Hiroyuki Sumi, PhD, Gideon Bollag, PhD, Mark J. Levis, MD

Blood (2019) 134 (Supplement_1): 1373.

https://doi.org/10.1182/blood-2019-124030

Published: 2019

Journal Articles

MN1 Expression Is an Indepedent Prognostic Marker in FLT3-Mutated Acute Myeloid Leukemia and Is Involved in the Resistance to FLT3 Inhibitors

Diego A Pereira-Martins, MSc, Juan L Coelho-Silva, BSc, MSc, Isabel Weinhäuser, MSc, Carol Hassibe Thomé, César Alexander Ortiz Rojas, BSc, Luíse A A Simões, BSc, Fabiola Traina, MD PhD, Michael Heuser, MD, Arnold Ganser, MD, Antonio R. Lucena-Araujo, PhD, Eduardo M Rego, MD PhD

Blood (2019) 134 (Supplement_1): 1403.

https://doi.org/10.1182/blood-2019-131542

Published: 2019

Journal Articles

Younger Patients with Newly Diagnosed FLT3-Mutant AML Treated with Crenolanib Plus Chemotherapy Achieve Adequate Free Crenolanib Levels and Durable Remissions

Aaron D Goldberg, MD PhD, Catherine C. Coombs, MD, Eunice S. Wang, MD, Roland B. Walter, MD PhD MS, Chatchada Karanes, MD, Carlos Enrique Vigil, MD, Boo Messahel, MD, Richard M. Stone, MD, Robert H. Collins, MD

Blood (2019) 134 (Supplement_1): 1326.

https://doi.org/10.1182/blood-2019-130863

Published: 2019

Journal Articles

A Phase 2a Open-Label Study to Investigate Safety and Tolerability (including the MTD), Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-3724 in Combination with Lenalidomide in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Christine Burnett, Gary Gordon, MD PhD, Thomas Strack, MD, Tara Lehner, MS, PMP, Jack P Higgins, PhD, Jason Tache, DO

Blood (2019) 134 (Supplement_1): 1597.

https://doi.org/10.1182/blood-2019-128503

Published: 2019

Journal Articles

Mutations and Copy Number Gains of the BCL2 Family Members Mediate Resistance to Venetoclax in Multiple Myeloma (MM) Patients

Paola Neri, MD PhD, Ranjan Maity, PhD, Jean-Baptiste Alberge, Sarthak Sinha, BSc, Justin Donovan, Madison Kong, Fajer Hasan, Arzina Jaffer, Lawrence H. Boise, PhD, Nizar Bahlis, MD

Blood (2019) 134 (Supplement_1): 572.

https://doi.org/10.1182/blood-2019-127593

Published: 2019

Journal Articles

LOXO-305: Targeting C481S Bruton Tyrosine Kinase in Patients with Ibrutinib-Resistant CLL

Aishath S Naeem, PhD, Winnie I Nguy, Svitlana Tyekucheva, PhD, Stacey M. Fernandes, BS, Vanessa Rai, BS, Kevin Ebata, PhD, Eliana B. Gomez, PhD, Barb J. Brandhuber, PhD, Stephen M. Rothenberg, MD PhD, Jennifer R Brown, MD PhD

Blood (2019) 134 (Supplement_1): 478.

https://doi.org/10.1182/blood-2019-124362

Published: 2019

Journal Articles

The Tissue Factor Pathway Inhibitor Gamma Knockout Mouse Is a Better Model Than the Wild Type Mouse for Studying Tissue Factor-Related Human Diseases

Thomas J. Girard, Nina M. Lasky, Dhanalakshmi S. Anbukumar, George J. Broze, Jr.

Blood (2019) 134 (Supplement_1): 484.

https://doi.org/10.1182/blood-2019-130360

Published: 2019

Journal Articles

Characterization of the Interaction between Tissue Factor Pathway Inhibitor α (TFPIα) and Factor V Species

Teodolinda Petrillo, PhD, Cornelis Van 't Veer, PhD, Rodney M. Camire, PhD

Blood (2019) 134 (Supplement_1): 485.

https://doi.org/10.1182/blood-2019-130589

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice

Structural characterization of a novel GPVI-nanobody complex reveals a biologically active domain-swapped GPVI dimer

Protease activity in single-chain prekallikrein

Characterisation of Citrullinated TFPI and Truncated TFPI Constructs By PAD4 in Model and Plasma Systems

In Vitro and In Vivo Characterization of Marstacimab, an Anti-TFPI Antibody

Prospective Controlled Monitoring of Hemlibra Prophylaxis Initiation in a Large Cohort of Hemophilia a Patients- Real World Data

Analysis of Platelet Alpha and Dense Granule Release Using Small Volumes of Blood

Comparison of Bypassing Agents in Patients on Emicizumab Using Global Hemostasis Assays

Oxphos Inhibition Induces Formation of Tunneling Nanotubes in AML Cells and Facilitates Mitochondrial Transfer from BM Stroma to AML That Contributes to Microenvironment-Mediated Drug-Resistance of AML

Expansion of Prior Existing TP53 Mutated Clones in Polycythemia Vera Patients Treated with Idasanutlin

Exploiting the Zinc Finger Degrome Targeted By Lenalidomide to Engineer Reversible Off-Switch Degradable Chimeric Antigen Receptors

Glutaminase Inhibition Overcomes Acquired Resistance to Mitochondrial Complex I in NOTCH1-Driven T-Cell Acute Lymphoblastic Leukemias (T-ALL) Via Block of Glutamine Driven Reductive Metabolism

A Novel Combination Regimen of BET and FLT3 Inhibition for FLT3-ITD Acute Myeloid Leukemia

MN1 Expression Is an Indepedent Prognostic Marker in FLT3-Mutated Acute Myeloid Leukemia and Is Involved in the Resistance to FLT3 Inhibitors

Younger Patients with Newly Diagnosed FLT3-Mutant AML Treated with Crenolanib Plus Chemotherapy Achieve Adequate Free Crenolanib Levels and Durable Remissions

A Phase 2a Open-Label Study to Investigate Safety and Tolerability (including the MTD), Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-3724 in Combination with Lenalidomide in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Mutations and Copy Number Gains of the BCL2 Family Members Mediate Resistance to Venetoclax in Multiple Myeloma (MM) Patients

LOXO-305: Targeting C481S Bruton Tyrosine Kinase in Patients with Ibrutinib-Resistant CLL

The Tissue Factor Pathway Inhibitor Gamma Knockout Mouse Is a Better Model Than the Wild Type Mouse for Studying Tissue Factor-Related Human Diseases

Characterization of the Interaction between Tissue Factor Pathway Inhibitor α (TFPIα) and Factor V Species

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only